Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.74 |
| ▸ | EGFR | P00533 | 7/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19997516 | 0.86 | BTK (0.55) | BTKEGFRSRC | |
| SCHEMBL19424176 | 0.86 | BTK (0.77) | BTKEGFRSRC | |
| SCHEMBL18700071 | 0.86 | BTK (0.76) | BTKEGFRSRC | |
| SCHEMBL18700147 | 0.86 | BTK (0.76) | BTKEGFRSRC | |
| SCHEMBL15472582 | 0.85 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL15669774 | 0.85 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL15756482 | 0.85 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL18472776 | 0.84 | BTK (0.85) | BTKEGFRSRC | |
| SCHEMBL18853844 | 0.84 | BTK (0.85) | BTKEGFRSRC | |
| SCHEMBL15763029 | 0.84 | BTK (0.73) | BTKEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20170224688-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170143712-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224688-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | BTK, SYK, LCK | BTK 1/4885EGFR 391/4885SRC 24/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885EGFR 357/4885SRC 8/4885 |
| US-20170143712-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | BTK, LCK, SYK | BTK 1/4885EGFR 153/4885SRC 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.